{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:49:36Z","timestamp":1791308976460,"version":"4.3.1"},"reference-count":48,"publisher":"BMJ","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Dis Child Fetal Neonatal Ed"],"published-print":{"date-parts":[[2008,11]]},"abstract":"<jats:sec>\n                  <jats:title>Background:<\/jats:title>\n                  <jats:p>Intermittent infusion of vancomycin is widely used to treat late-onset sepsis in neonates. On the other hand, the continuous infusion of vancomycin could improve bactericidal efficacy since its action is time dependent.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective:<\/jats:title>\n                  <jats:p>To evaluate a simplified dosage schedule for continuous-infusion vancomycin therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p>Prospective study in premature neonates (&lt;34 weeks) with suspected coagulase-negative staphylococci (CoNS) sepsis. Before antibiotics at time zero (T0), serum creatinine was measured and blood cultures were collected. Vancomycin dosage began with 25 mg\/kg\/day or 15 mg\/kg\/day (period 1) and 30 mg\/kg\/day or 20 mg\/kg\/day (period 2) depending on whether serum creatinine was below or above 90 \u03bcmol\/l. Two days after beginning treatment (first timepoint: T1), serum vancomycin was measured and second blood cultures were collected.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>Between June 2002 and December 2005, 145 neonates were evaluated. At birth, the median (interquartile range) body weight was 920 (500\u20131160) g and gestational age was 28 (26\u201329) weeks. At T1, serum vancomycin was within the required range in 74.5% of neonates (108\/145). Serum vancomycin levels were higher in period 2 than in period 1 (20 mg\/l vs 13 mg\/l, p&lt;0.05). At T0, 55% (80\/145) of blood cultures were positive for CoNS, but 71% (57\/80) were negative at T1. Four days after beginning treatment, 92% of subjects had recovered without removing the central venous catheter.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion:<\/jats:title>\n                  <jats:p>Using this simplified dosage schedule, bactericidal efficacy was maintained and most subjects had serum vancomycin concentrations within the therapeutic range.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/adc.2007.128280","type":"journal-article","created":{"date-parts":[[2008,5,4]],"date-time":"2008-05-04T07:52:54Z","timestamp":1209887574000},"page":"F418-F421","source":"Crossref","is-referenced-by-count":42,"title":["Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented Gram-positive infections: a new dosage schedule"],"prefix":"10.1136","volume":"93","author":[{"given":"O","family":"Plan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Cambonie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Barbotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Devine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Milesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Pidoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Badr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J C","family":"Picaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2008,5,1]]},"reference":[{"key":"2025090511442646000_93.6.F418.1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.110.2.285"},{"key":"2025090511442646000_93.6.F418.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197606102942403"},{"key":"2025090511442646000_93.6.F418.3","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/169.3.526"},{"key":"2025090511442646000_93.6.F418.4","doi-asserted-by":"publisher","DOI":"10.1542\/peds.110.4.e42"},{"key":"2025090511442646000_93.6.F418.5","doi-asserted-by":"publisher","DOI":"10.1086\/425321"},{"key":"2025090511442646000_93.6.F418.6","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1128\/AAC.28.5.634","article-title":"Comparison of the activities of coumermycin, ciprofloxacin, teicoplanin, and other non-\u03b2-lactam antibiotics against clinical isolates of methicillin-resistant staphylococcus aureus from various geographical locations.","volume":"28","author":"Aldridge","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"2025090511442646000_93.6.F418.7","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.30.6.823"},{"key":"2025090511442646000_93.6.F418.8","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.8.1766"},{"key":"2025090511442646000_93.6.F418.9","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0022-3476(88)80107-0","article-title":"Vancomycin reactions in preterm infants.","volume":"112","author":"Barton","year":"1988","journal-title":"J Pediatr"},{"key":"2025090511442646000_93.6.F418.10","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/00006454-199301000-00026","article-title":"Vancomycin-associated shock in neonates.","volume":"12","author":"Anglada","year":"1993","journal-title":"Pediatr Inf Dis J"},{"key":"2025090511442646000_93.6.F418.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(87)80133-6"},{"key":"2025090511442646000_93.6.F418.12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.1.52"},{"key":"2025090511442646000_93.6.F418.13","first-page":"282","article-title":"Vancomycin pharmacokinetics in very low birth weight neonates.","volume":"8","author":"Leonard","year":"1989","journal-title":"Pediatr Infect Dis J"},{"key":"2025090511442646000_93.6.F418.14","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-198709000-00024"},{"key":"2025090511442646000_93.6.F418.15","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199508000-00001"},{"key":"2025090511442646000_93.6.F418.16","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00763.x"},{"key":"2025090511442646000_93.6.F418.17","first-page":"525","article-title":"Perfusion continue de vancomycine en p\u00e9riode n\u00e9onatale.","volume":"42","author":"Borderon","year":"1994","journal-title":"Path Biol"},{"key":"2025090511442646000_93.6.F418.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02725.x"},{"key":"2025090511442646000_93.6.F418.19","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.9.2460-2467.2001"},{"key":"2025090511442646000_93.6.F418.20","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/01.inf.0000078160.29072.42","article-title":"Linezolid Pediatric Study Group. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children.","volume":"22","author":"Kaplan","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"2025090511442646000_93.6.F418.21","first-page":"1729","article-title":"Stability of vancomycin hydrochloride in 5% dextrose and 0.9% sodium chloride injections.","volume":"43","author":"Das Gupta","year":"1986","journal-title":"Am J Hosp Pharm"},{"key":"2025090511442646000_93.6.F418.22","first-page":"A","article-title":"Ceftazidime and vancomycin constant-rate infusion in neutropenic children: pharmacokinetic parameters and clinical implications.","volume":"37","author":"Le Normand","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"2025090511442646000_93.6.F418.23","doi-asserted-by":"publisher","DOI":"10.1159\/000014053"},{"key":"2025090511442646000_93.6.F418.24","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-0529"},{"key":"2025090511442646000_93.6.F418.25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/07315724.1983.10719910","article-title":"Limitation of central vein thrombosis in total parenteral nutrition by continuous infusion of low-dose heparin.","volume":"2","author":"Imperial","year":"1983","journal-title":"J Am Coll Nutr"},{"key":"2025090511442646000_93.6.F418.26","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/154.2.349"},{"key":"2025090511442646000_93.6.F418.27","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1128\/AAC.16.5.655","article-title":"Susceptibility and synergy studies of methicillin-resistant Staphylococcus epidermidis.","volume":"16","author":"Ein","year":"1979","journal-title":"Antimicrob Agents Chemother"},{"key":"2025090511442646000_93.6.F418.28","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1128\/AAC.38.6.1325","article-title":"Comparative prophylactic efficacies of ciprofloxacin, ofloxacin, cefazolin and vancomycin in experimental model of staphylococcal wound infection.","volume":"38","author":"Kernodle","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"2025090511442646000_93.6.F418.29","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1177\/106002809302700514","article-title":"Vancomycin therapeutic drug monitoring: is it necessary?","volume":"27","author":"Freeman","year":"1993","journal-title":"Ann Pharmacother"},{"key":"2025090511442646000_93.6.F418.30","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(84)80036-0"},{"key":"2025090511442646000_93.6.F418.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(69)80224-6"},{"key":"2025090511442646000_93.6.F418.32","first-page":"1805","article-title":"Infections ventriculaires \u00e0 staphylocoque: traitement par la vancomycine en perfusion veineuse continue.","volume":"15","author":"Barois","year":"1986","journal-title":"Presse Med"},{"key":"2025090511442646000_93.6.F418.33","doi-asserted-by":"publisher","DOI":"10.1136\/fn.81.3.F221"},{"key":"2025090511442646000_93.6.F418.34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1590\/S0041-87812001000100004","article-title":"Monitoring the treatment of sepsis with vancomycin in term newborn infants.","volume":"56","author":"Machado","year":"2001","journal-title":"Rev Hosp Clin Fac Med S Paulo"},{"key":"2025090511442646000_93.6.F418.35","first-page":"129","article-title":"Prospective evaluation of the vancomycin dosage guideline for neonates.","volume":"10","author":"Gabriel","year":"1991","journal-title":"Clin Pharm"},{"key":"2025090511442646000_93.6.F418.36","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199733010-00004"},{"key":"2025090511442646000_93.6.F418.37","doi-asserted-by":"publisher","DOI":"10.1007\/BF00637600"},{"key":"2025090511442646000_93.6.F418.38","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(80)80347-7"},{"key":"2025090511442646000_93.6.F418.39","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(02)00027-4"},{"key":"2025090511442646000_93.6.F418.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.siny.2004.10.004"},{"key":"2025090511442646000_93.6.F418.41","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.26.876"},{"key":"2025090511442646000_93.6.F418.42","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/clinchem\/44.5.1129","article-title":"Laboratory guidelines for monitoring antimicrobial drugs. National academy of clinical biochemistry.","volume":"44","author":"Hammett-Stabler","year":"1998","journal-title":"Clin Chem"},{"key":"2025090511442646000_93.6.F418.43","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00850.x"},{"key":"2025090511442646000_93.6.F418.44","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/00006454-198605000-00006","article-title":"Vancomycin pharmacokinetics in infants: relationships to indices of maturation.","volume":"5","author":"Schaible","year":"1986","journal-title":"Pediatr Infect Dis"},{"key":"2025090511442646000_93.6.F418.45","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000480922","article-title":"Vancomycin pharmacokinetics in infants: relationship to postconceptional age and serum creatinine.","volume":"14","author":"Kildoo","year":"1989","journal-title":"Dev Pharmacol Ther"},{"key":"2025090511442646000_93.6.F418.46","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0272-6386(83)80064-X","article-title":"Stability of single and combination antimicrobial agents in various peritoneal dialysates in the presence of insulin and heparin.","volume":"3","author":"Sewell","year":"1983","journal-title":"Am J Kidney Dis"},{"key":"2025090511442646000_93.6.F418.47","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1177\/106002809402800503","article-title":"Stability of ceftazidime and vancomycin alone and in combination in heparinized and non heparinized peritoneal dialysis solution.","volume":"28","author":"Vaughan","year":"1994","journal-title":"Ann Pharmacother"},{"key":"2025090511442646000_93.6.F418.48","doi-asserted-by":"publisher","DOI":"10.1177\/0148607192016003268"}],"container-title":["Archives of Disease in Childhood - Fetal and Neonatal Edition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/adc.2007.128280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T19:00:32Z","timestamp":1757098832000},"score":1,"resource":{"primary":{"URL":"https:\/\/fn.bmj.com\/lookup\/doi\/10.1136\/adc.2007.128280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,1]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2008,10,21]]},"published-print":{"date-parts":[[2008,11]]}},"alternative-id":["10.1136\/adc.2007.128280"],"URL":"https:\/\/doi.org\/10.1136\/adc.2007.128280","relation":{},"ISSN":["1359-2998","1468-2052"],"issn-type":[{"value":"1359-2998","type":"print"},{"value":"1468-2052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,1]]}}}